Freedman Financial Associates, Inc. Blueprint Medicines Corp Transaction History
Freedman Financial Associates, Inc.
- $0
- Q2 2022
Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$585 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$576 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$517 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$285 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$217 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.26B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...